Autres langues Cipla Limited

Actions

CIPLA

INE059A01026

Produits pharmaceutiques

Temps Différé 08:01:00 04/09/2026 Varia. 5j. Varia. 1 janv.
1 390,30 INR -0,32 % Graphique intraday de Cipla Limited -2,28 % -7,96 %

Autres langues

03/09 India's Cipla, China's Qilu partner for US launch of Merck's Keytruda biosimilar
25/08 Cipla's Pithampur, India Unit Gets 7 Observations From US FDA
14/08 Patent Disputes Over AI-Assisted Product Features In Consumer Apps
14/08 Cipla Announces Appointment of Runa Akhtar to Marketing Head, Cipla Urology
11/08 Global drugmakers invest billions to boost US presence
06/08 South African Patent Ruling In Favour Of Astellas Pharma
28/07 Cipla Limited Receives U.S. Fda Approval for Generic Advair Diskus
23/07 Cipla Redesignates Global CFO to New Internal Role; Names New CFO
23/07 Cipla Limited Reports Earnings Results for the First Quarter Ended June 30, 2026
23/07 Cipla Limited Announces Cessation of Sanjay Joseph as Senior Managerial Personnel, Effective July 24, 2026
23/07 Cipla Limited Announces Global Chief Financial Officer Changes
23/07 Cipla Limited Announces Executive Changes
23/07 India's Cipla posts another profit decline, names insider Dinesh Jain CFO
22/07 Trump will Generika-Produktion mit massiven Zöllen in die USA zwingen
07/07 India finds Adani's Mumbai airport shops sold nicotine pouches in breach of law
16/06 Cipla Limited Appoints Shivam Puri as Chief Executive Officer of Its One India Business, Effective July 1, 2026
15/06 Global drugmakers invest billions to boost US presence
12/06 India raises price cap on cancer drugs to tackle shortage
11/06 Cipla's Goa, India Facility Receives VAI Status from US FDA
09/06 Indian cancer patients battle shortage of key drugs as platinum costs surge
22/05 India's Sun Pharma posts profit beat on specialty drug demand, shares slide on cost pressures
14/05 Cipla Limited announces Annual dividend, payable on July 25, 2026
13/05 Cipla Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026
13/05 Indian drugmaker Cipla misses Q4 profit view on weak US sales
13/05 Cipla Q4 consol net profit 5.55 billion rupees
Aucun résultat pour cette recherche
🔇